Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

On Tuesday, the stock fell by 8% after the company forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates. The stock has gained 434.64% over the last 5 years ...

Pfizer has discontinued its experimental weight-loss pill danuglipron after a trial patient experienced potential ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current ... U.S. prescription data for Novo's Wegovy and Lilly's Zepbound. Barclays in a note on Friday said prescriptions ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...